Goldman Sachs analysts removed Amgen (AMGN) from the firm’s US Conviction List as part of its monthly update.Don't Miss our Black Friday ...
The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback